Twist Bioscience Quarterly Income Statements Chart
Quarterly
|
Annual
Twist Bioscience Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues | 96,057,000 | 92,793,000 | 88,713,000 | 84,710,000 | 81,464,000 | 75,302,000 | 71,498,000 | 66,946,000 | 63,740,000 | 60,180,000 | 54,243,000 | 57,306,000 | 56,113,000 | 48,127,000 | 42,018,000 | 37,951,000 | 35,018,000 | 31,204,000 | 28,161,000 | 32,432,000 | 21,207,000 | 19,297,000 | 17,164,000 | 15,737,000 | 13,600,000 | 13,557,000 | 11,492,000 | |
| yoy | 17.91% | 23.23% | 24.08% | 26.53% | 27.81% | 25.13% | 31.81% | 16.82% | 13.59% | 25.04% | 29.09% | 51.00% | 60.24% | 54.23% | 49.21% | 17.02% | 65.12% | 61.70% | 64.07% | 106.09% | 55.93% | 42.34% | 49.36% | |||||
| qoq | 3.52% | 4.60% | 4.73% | 3.98% | 8.18% | 5.32% | 6.80% | 5.03% | 5.92% | 10.95% | -5.34% | 2.13% | 16.59% | 14.54% | 10.72% | 8.38% | 12.22% | 10.81% | -13.17% | 52.93% | 9.90% | 12.43% | 9.07% | 15.71% | 0.32% | 17.97% | ||
| costs and expenses: | ||||||||||||||||||||||||||||
| cost of revenues | 44,760,000 | 46,765,000 | 45,873,000 | 46,477,000 | 46,193,000 | 44,420,000 | 42,536,000 | 42,424,000 | 41,845,000 | 41,669,000 | 29,442,000 | 31,586,000 | 30,974,000 | 29,714,000 | 27,056,000 | 22,497,000 | 20,933,000 | 19,028,000 | 18,162,000 | 17,577,000 | 16,472,000 | 13,564,000 | 13,792,000 | 12,385,000 | 11,394,000 | 11,789,000 | 11,857,000 | |
| research and development expenses | 18,047,000 | |||||||||||||||||||||||||||
| selling, general and administrative expenses | 63,370,000 | |||||||||||||||||||||||||||
| impairment of long-lived assets | 44,930,000 | |||||||||||||||||||||||||||
| total costs and expenses | 126,177,000 | |||||||||||||||||||||||||||
| income from operations | -30,120,000 | -41,560,000 | -34,644,000 | -36,043,000 | -88,922,000 | -48,889,000 | -46,977,000 | -50,112,000 | -60,781,000 | -61,637,000 | -44,630,000 | -56,871,000 | -61,163,000 | -60,802,000 | -55,940,000 | -39,811,000 | -42,118,000 | -38,004,000 | -32,793,000 | -23,967,000 | -28,196,000 | -32,086,000 | -55,830,000 | -31,568,000 | -28,121,000 | -26,263,000 | -22,897,000 | |
| yoy | -66.13% | -14.99% | -26.25% | -28.08% | 46.30% | -20.68% | 5.26% | -11.88% | -0.62% | 1.37% | -20.22% | 42.85% | 45.22% | 59.99% | 70.59% | 66.11% | 49.38% | 18.44% | -41.26% | -24.08% | 0.27% | 22.17% | 143.83% | |||||
| qoq | -27.53% | 19.96% | -3.88% | -59.47% | 81.89% | 4.07% | -6.26% | -17.55% | -1.39% | 38.11% | -21.52% | -7.02% | 0.59% | 8.69% | 40.51% | -5.48% | 10.83% | 15.89% | 36.83% | -15.00% | -12.12% | -42.53% | 76.86% | 12.26% | 7.07% | 14.70% | ||
| operating margin % | -31.36% | -44.79% | -39.05% | -42.55% | -109.15% | -64.92% | -65.70% | -74.85% | -95.36% | -102.42% | -82.28% | -99.24% | -109.00% | -126.34% | -133.13% | -104.90% | -120.28% | -121.79% | -116.45% | -73.90% | -132.96% | -166.27% | -325.27% | -200.60% | -206.77% | -193.72% | -199.24% | |
| interest income | 2,690,000 | 2,801,000 | 3,240,000 | 3,620,000 | 3,663,000 | 3,941,000 | 4,120,000 | 3,893,000 | 3,968,000 | 3,464,000 | 3,040,000 | 1,928,000 | 722,000 | 259,000 | 154,000 | 58,000 | 86,000 | 157,000 | 134,000 | 111,000 | 247,000 | 576,000 | 564,000 | 789,000 | 804,000 | 775,000 | 664,000 | |
| gain on sale of business | 48,847,000 | |||||||||||||||||||||||||||
| other income, net [2] | -836,000 | |||||||||||||||||||||||||||
| income before income taxes | 20,581,000 | -39,153,000 | -31,497,000 | -34,751,000 | -85,380,000 | -45,147,000 | -42,888,000 | -46,465,000 | -56,773,000 | -58,480,000 | -41,748,000 | -50,823,000 | -60,666,000 | -60,817,000 | -55,968,000 | -40,901,000 | -42,414,000 | -37,858,000 | -32,854,000 | -24,056,000 | -28,186,000 | -31,707,000 | -55,601,000 | -31,068,000 | -27,862,000 | -25,849,000 | -22,596,000 | |
| income tax expense | -191,000 | -175,000 | -97,000 | |||||||||||||||||||||||||
| net income | 20,390,000 | -39,328,000 | -31,594,000 | |||||||||||||||||||||||||
| yoy | ||||||||||||||||||||||||||||
| qoq | -151.85% | 24.48% | ||||||||||||||||||||||||||
| net income margin % | 21.23% | -42.38% | -35.61% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| other comprehensive income: | ||||||||||||||||||||||||||||
| change in unrealized gain on investments | -25,000 | 30,000 | -66,000 | 147,000 | -21,000 | -57,000 | 647,000 | -1,113,000 | 277,000 | -4,000 | -12,000 | 13,000 | -74,000 | 12,000 | 36,000 | 3,000 | 20,000 | |||||||||||
| foreign currency translation adjustment | -177,000 | -25,000 | -61,000 | 66,000 | -54,000 | -38,000 | 57,000 | -323,000 | -538,000 | 73,000 | -366,000 | -666,000 | -498,000 | 275,000 | -94,000 | 122,000 | 250,000 | 38,000 | 63,000 | -5,000 | 11,000 | -7,000 | 28,000 | 250,000 | -180,000 | -56,000 | ||
| comprehensive income | 20,188,000 | |||||||||||||||||||||||||||
| basic earnings per share: | ||||||||||||||||||||||||||||
| net income per share | 0.34 | -0.66 | -0.53 | -0.59 | -1.47 | -0.79 | -0.75 | -0.81 | -1.01 | -1.04 | -0.74 | -0.89 | -1.08 | -1.13 | -0.91 | -0.83 | -0.82 | -0.78 | -0.72 | -0.48 | -0.67 | -0.85 | -1.69 | -0.95 | -0.92 | -0.93 | -1.18 | |
| weighted-average shares used for eps calculation | 59,995 | 59,649 | 59,162 | 58,016 | 58,145 | 57,779 | 57,497 | 56,885 | 57,041 | 56,777 | 56,444 | 53,885 | 56,287 | 53,472 | 49,912 | 48,251 | 48,963 | 48,709 | 46,000 | 39,190 | 41,838,498 | 37,163,684 | 32,976,145 | 27,461,844 | 30,290,150 | 27,891,700 | 19,187,533 | |
| diluted earnings per share: | ||||||||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||||||
| research and development | 23,917,000 | 21,307,000 | 21,134,000 | 22,469,000 | 24,149,000 | 23,099,000 | 23,746,000 | 24,528,000 | 27,379,000 | 31,242,000 | 29,606,000 | 36,840,000 | 31,231,000 | 22,630,000 | 19,443,000 | 19,838,000 | 15,791,000 | 14,000,000 | 11,637,000 | 10,444,000 | 10,629,000 | 10,297,000 | 10,497,000 | 9,007,000 | 8,907,000 | 7,273,000 | ||
| selling, general and administrative | 63,671,000 | 56,177,000 | 53,142,000 | 56,794,000 | 55,622,000 | 52,840,000 | 47,391,000 | 46,057,000 | 53,965,000 | 42,324,000 | 54,159,000 | 53,693,000 | 53,998,000 | 51,098,000 | 38,243,000 | 34,478,000 | 34,389,000 | 28,792,000 | 27,185,000 | 22,487,000 | 27,190,000 | 26,405,000 | 24,423,000 | 21,320,000 | 19,124,000 | 15,259,000 | ||
| total operating expenses | 134,353,000 | 123,357,000 | 120,753,000 | 170,386,000 | 124,191,000 | 118,475,000 | 117,058,000 | 124,521,000 | 121,817,000 | 98,873,000 | 114,177,000 | 117,276,000 | 108,929,000 | 97,958,000 | 77,762,000 | 77,136,000 | 69,208,000 | 60,954,000 | 56,399,000 | 49,403,000 | 51,383,000 | 72,994,000 | 47,305,000 | 41,721,000 | 39,820,000 | 34,389,000 | ||
| interest expense | -143,000 | -24,000 | -1,000 | -1,000 | -2,000 | -1,000 | -26,000 | -29,000 | -26,000 | -83,000 | -70,000 | -95,000 | -118,000 | -143,000 | -181,000 | -215,000 | -248,000 | -287,000 | -318,000 | -340,000 | -348,000 | |||||||
| other income | -251,000 | -69,000 | -2,299,000 | -121,000 | -199,000 | -31,000 | -245,000 | 41,000 | -305,000 | -157,000 | -461,000 | -225,000 | -245,000 | -156,000 | -1,065,000 | -312,000 | 84,000 | -77,000 | -57,000 | -56,000 | 18,000 | -87,000 | -2,000 | -227,000 | -21,000 | -15,000 | ||
| other comprehensive loss: | ||||||||||||||||||||||||||||
| comprehensive loss | -39,323,000 | -31,721,000 | -34,442,000 | -85,646,000 | -45,587,000 | -42,817,000 | -46,364,000 | -58,141,000 | -58,436,000 | -43,058,000 | -51,581,000 | -61,419,000 | -61,506,000 | -45,380,000 | -41,124,000 | -39,799,000 | -37,871,000 | -32,845,000 | -24,365,000 | -28,286,000 | -31,745,000 | -55,629,000 | -31,117,000 | -27,663,000 | -26,093,000 | -22,702,000 | ||
| restructuring and other costs | ||||||||||||||||||||||||||||
| change in fair value of contingent considerations and holdbacks | -581,000 | -1,196,000 | -4,135,000 | -1,174,000 | -4,231,000 | -6,014,000 | ||||||||||||||||||||||
| income tax provision | -164,000 | -191,000 | -345,000 | -120,000 | ||||||||||||||||||||||||
| net income attributable to common stockholders | -34,655,000 | -85,571,000 | -45,492,000 | -43,008,000 | -46,243,000 | -57,395,000 | -59,156,000 | -41,824,000 | -51,115,000 | -60,517,000 | -60,668,000 | -45,563,000 | -41,242,000 | -40,037,000 | -37,919,000 | -32,900,000 | -24,318,000 | -28,207,000 | -31,768,000 | -55,638,000 | -31,181,000 | -27,916,000 | -25,933,000 | -22,639,000 | ||||
| change in unrealized (gain) loss on investments | 134,000 | |||||||||||||||||||||||||||
| restructuring costs | 3,168,000 | 12,672,000 | ||||||||||||||||||||||||||
| benefit from / income taxes | -343,500 | -622,000 | ||||||||||||||||||||||||||
| change in unrealized loss on investments | 327,000 | -208,000 | -868,000 | -448,500 | -404,000 | 16,000 | -7,000 | |||||||||||||||||||||
| income tax (provision) / benefit | -676,000 | -76,000 | ||||||||||||||||||||||||||
| benefit from income taxes | -292,000 | 149,000 | 149,000 | 10,405,000 | -341,000 | 2,377,000 | -61,000 | -46,000 | -262,000 | -21,000 | -61,000 | -37,000 | -113,000 | -54,000 | -84,000 | -43,000 | ||||||||||||
| change in fair value of contingent considerations and indemnity holdbacks | -2,826,000 | |||||||||||||||||||||||||||
| change in fair value of acquisition consideration | 471,750 | 1,887,000 | ||||||||||||||||||||||||||
| litigation settlement | 22,500,000 | |||||||||||||||||||||||||||
| change in unrealized income on investments | 10,000 | |||||||||||||||||||||||||||
| change in unrealized income/(loss) on investments | -8,000 |
We provide you with 20 years income statements for Twist Bioscience stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Twist Bioscience stock. Explore the full financial landscape of Twist Bioscience stock with our expertly curated income statements.
The information provided in this report about Twist Bioscience stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.